ClinicalTrials.gg
CompletedNCT03830723PITSUpdated Sep 13, 2022

Personalized Insemination Treatment Study

A Phase 2 interventional study of Follitropin delta in Infertility, Intrauterine Insemination and Reproduction, sponsored by Clinique Ovo. Completed at 1 site in Canada. Open to female participants aged 18 Years to 42 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-13.

Sponsored by Clinique Ovo · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years to 42 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.

Enrollment
10th of 13
110 · median 220
Started
2020
the only one that year
Phase 2
5 of 13
1 open now
Registered
7th of 13
by date
Lead sponsor
1 of 13
Clinique Ovo

Among the 13 studies testing follitropin delta in Infertility, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 5 in phase 2, and was the 7th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About follitropin delta

follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 42 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing follitropin delta in Infertility, or all of them as a file.
02

Study summary

This study is intended for women undergoing their first cycle of 3 intrauterine inseminations. All 3 inseminations will be personalized by using algorithms to determine the dose of study medication.

Read the detailed description

Study medication dosage for the first insemination cycle will be based on the woman's age as well as her Anti-Mullerian Hormone (AMH) levels.

Study medication dosage for the second and third insemination will depend on ovarian response (number of follicles) during previous insemination cycle and woman's age

03

Conditions studied

  • Infertility
  • Intrauterine Insemination
  • Reproduction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women having consented to the study
  • Women followed at fertility center
  • First IUI cycle
  • Women between the ages of 18 to 42 inclusively at time of consent form signature
  • AMH \< 35 pmol/L (4.9 ng/mL) in participants' file in the last 24 months
  • At least one permeable Fallopian tube confirmed by laparoscopy, hysterosalpingography (HSG), hysterosalpingosonography (HSSG) or one pregnancy in the last 3 years
  • Insemination with either partner or donor sperm
  • Male partner semen analysis considered adequate for IUI in accordance to the centre's standard practice
  • Menstrual cycles from 26 to 39 days
  • Presence of both ovaries

Exclusion criteria

Exclusion Criteria:

  • Unable to consent
  • Body weight >100 kg
  • AMH ≥35 pmol/L (4.9 ng/mL) in participants' file in the last 24 months
  • Severe malformation (unicornuate or bicornuate uterus) or uterine anomaly including fibroids ≥ 5 cm
  • Uncontrolled thyroid or adrenal dysfunction
  • Pituitary tumour
  • Persistent ovarian cysts or enlargement not due to PCOS (Polycystic ovary syndrome) > 3 cm
  • Anovulatory women
  • Use of in the last 3 months prior to start of stimulation
  • Diagnosis of hydrosalpinx
  • Breast pathology incompatible with gonadotropin stimulation
  • to follitropin delta or to any ingredient in the formulation
  • Addition of other infertility medication that can influence follicle stimulation and maturation such as growth hormone (GH)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Other
    Rekovelle (Follitropin delta)

    All participants will receive a prescription for study medication Rekovelle (follitropin delta)

    Drug: Follitropin delta

Interventions

  • Study medication doses during all 3 insemination will be personalized using a suggested algorithm

    Also known as: Rekovelle

06

What researchers measure

Primary outcomes

  1. Ovarian response

    Evaluate the dose-response Relationship of Rekovelle with respect to ovarian response in participants undergoing controlled ovarian stimulation for intrauterine insemination

    Time frame: 1 year

Secondary outcomes

  1. Pregnancy rate

    Evaluate pregnancy rate 6-8 weeks after insemination by ultrasound

    Time frame: 1 year

07

Study locations

1 site
  • Clinique Ovo
    Montréal, Quebec H4P 2S4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Jan 2021, 12 months.

Of 30 phase 2 interventional studies under Infertility, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2019
First posted
Feb 5, 2019
StartActual
Jan 9, 2020
Primary completionActual
Jan 20, 2021
CompletionActual
Sep 27, 2021
Last update
Sep 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03830723
Lead sponsor
Clinique Ovo
Responsible party
Sponsor
First posted
Feb 5, 2019
Start date
Jan 9, 2020
Primary completion
Jan 20, 2021
Completion
Sep 27, 2021
Last update
Sep 13, 2022

Study contacts

Jacques Kadoch, MD
principal investigator · Clinique Ovo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin delta

Start the discussion